Background The incidence of cardiovascular disease due to thrombosis is 2-4 folds greater in diabetic patients. Prothrombin time, activated partial thromboplastin time and platelet count are hematological indices that give an insight into the coagulation status. Hence, this study aims to assess the coagulation status of type II diabetic patients. Methods A comparative cross-sectional study was conducted at Bahir Dar Felege Hiwot referral hospital, Northwest Ethiopia. A total of 40 treated type II diabetic, 40 untreated diabetics and 40 non-diabetic subjects were included. After taking informed consent, structured questionnaire was used to collect socio-demographic data. Following interview, 4 ml of blood was collected to determine PT, aPTT and platelet count of the three groups. The data were entered into SPSS version 20 and analyzed. One-way ANOVA was used to compare means of PT, aPTT and platelet count among the groups. A P value less than 0.05 was considered as statistically significant. Results The mean aPTT of non-diabetic, treated and untreated type II diabetic patient was 32.8 ± 4.12 s, 34.4 ± 5.3 s, and 25.42 ± 8.46 s, respectively. The proportion of untreated diabetic patients with normal PT, aPTT and platelet counts was 60.0%, 7.5 and 92.5%, respectively. There was a significant shortening of aPTT in untreated diabetic as compared to both treated and nondiabetic controls (P < 0.001). Conclusions Shortening of aPTT in untreated type II diabetic patients might be useful marker in patients with diabetes. Therefore, monitoring the aPTT in newly diagnosed diabetic patients is important.
Background
Diabetes mellitus (DM) is metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. Etiologically, diabetes is classified into two; type I and type II diabetes mellitus [1] . Type II diabetes mellitus, previously called non-insulin dependent diabetes mellitus, is characterized by decreased insulin sensitivity which can subsequently provoke decreased insulin secretion as a result of Beta-cell loss [2] .
The International Diabetes Federation (IDF) has predicted that the number of individuals with diabetes will increase from 382 million in 2013 to 592 million in 2035, with 77% of the disease burden in lowland middle-income countries. Similarly, the IDF have also reported that in Ethiopia about 2 million people are expected to live with DM with the national prevalence of 4.4% in 2013 [3, 4] . Type II diabetic patients are at high risk for the development of thrombosis and bleeding disorders. Approximately 80% of patients die as a result of cardiovascular complications and its incidence due to thrombosis is 2-4 folds greater than the general population [5] .
Furthermore, prothrombin time (PT), activated partial thromboplastin time (aPTT) and platelet are hematological indices that give an insight into the coagulation status of patients. PT is a screening test used to detect disorders involving the activity of clotting factors (proteins) such as I, II, V, VII, and X of the extrinsic and common pathways while aPTT is used to screen for abnormalities of the intrinsic and common clotting systems and to monitor the anticoagulant effect of circulating heparin. It measures the activities of factors I, II, V, VIII, IX, X, XI, and XII of the intrinsic and common pathways [6] . However, there was no previous study that had been conducted concerning on evaluating the coagulation status of diabetes type II patients in the study area. Therefore, this study was aimed to assess the prothrombin time, activated partial thromboplastin time and platelet counts of type II diabetes mellitus at Bahir Dar Felege Hiwot referral hospital, Northwest Ethiopia.
Methods

Study setting and study population
A comparative cross-sectional study design was used to determine and compare PT, aPTT and PLT count of treated type II DM, untreated DM and healthy individuals. The study was conducted at Bahir Dar Felege Hiwot referral hospital from March to April, 2015. This hospital is found in Bahir Dar town which is 546 km from Addis Ababa in the Northwest Ethiopia. The hospital provides services for more than 800 new out patients and 5-10 follow-up diabetes patients per day.
According to the rules of thumb that has been recommended by VanVoorhis and Morgan, sample size of 30 for 80% power in each group are required to detect real differences [7] . Based on this suggestion, a total of 120 conveniently selected study subjects (40 treated type II DM patients, 40 untreated DM patients and 40 healthy controls) aged 30-60 years were included in this study. The study subjects were categorized in to three groups. Group I consisted of type II diabetic patients who had already started their non-insulin hypoglycemic drugs while group II included untreated newly diagnosis diabetic patients (fasting blood sugar (FBS) > 126 mg/dl or random blood sugar (RBS) > 180 mg/dl, had symptoms of diabetic and were confirmed by physician). On the other hand group II included those individuals who were apparently healthy and came to the hospital for medical checkup (Individuals who did nott have a diabetic history or symptom, any anticoagulant therapy, hypertensive, clinically proven liver dysfunction and whose FBS level was between 70 mg/dl and110 mg/dl) were studied. Treated type II diabetic and newly diagnosis DM patients on warfarin or heparin or any other anticoagulation therapy such as aspirin, and with other complications such as history of liver diseases, liver dysfunction, on hepatotoxic drugs, history of alcohol intake or cigarette smoking, hypertensive and psychic patients were excluded from the study. Apparently healthy individuals with any of DM symptom or who had taken any anticoagulant drug or who have a history of hypertensive were also excluded from the study.
Data collection and laboratory analysis
Sociodemographic data were collected with face to face interview after taking informed written consent followed by 4 ml of fasting blood collection. Then 1.8 ml blood sample was delivered into a test tube containing 0.2 ml tri-sodium citrate anticoagulant to keep 9:1 ratio of blood to anticoagulant. The blood was then centrifuged at approximately 3000 rpm for 15 min to prepare platelet poor plasma for aPTT and PT analysis. aPTT and PT were analyzed by using Huma Clot Duo plus instrument (HUMAN GmbH, Germany) [8] . The remaining blood was delivered into EDTA test tube for platelet count using HumaCount hematology analyzer (HUMAN GmbH, Germany) [9] .
To assure the quality of laboratory tests; proper labeling, patient identification and sample collection procedures were strictly followed. Quality control samples were also analyzed along the study subject samples. Appropriate recording, results interpretation and cross checking the result with its correspondence labeling were performed. Completeness of data was checked daily.
Statistical analysis
Data were entered in to SPSS version 20 for analysis. Descriptive statistics were used to describe the study groups. The Kolmogrov-Smirnov normality test was conducted and it showed that continuous variables were normally distributed among each group, so parametric tests were used. All continuous variables results were presented as mean ± standard deviation (SD) for each group. One-way ANOVA was used to compare means of PT, aPTT and platelet count among the groups. Tables and graphs were used to present the results. A P < 0.05 was considered as statistically significant.
Data availability All data supporting these findings is contained within the manuscript.
Results
Characteristics of study participants
A total of 120 study participants were included in this study. Of which, 40 were untreated DM patients, 40 were treated type II DM patients and the remaining 40 were healthy controls. The minimum and maximum age was 30 and 56 with the mean age of 40.57 ± 7.47 years in untreated, 37.80 ± 5.9 years in treated and 39.27 ± 6.59 years in healthy controls. About 62.5%, 75 and 62.5% of untreated DM, treated type II DM and non-diabetic controls were married, respectively. Furthermore, 70% of treated type II DM patients were treated using non-insulin hypoglycemic drug for less than 5 years and only 2% of treated type II DM were treated for more than 10 years with similar drug (Table 1) .
Laboratory findings
The proportion of untreated diabetic patients with normal PT, aPTT and platelet counts was 60.0%, 7.5 and 92.5%, respectively. Whereas, the proportion of treated diabetic patients with normal PT, aPTT and platelet counts was 85%, 95%, and 82.5%, respectively. Moreover, the proportion of treated diabetic patients with decreased aPTT and platelet count was 2.5 and 7.5%, respectively. There was no decreased PT value in treated DM patients. Whereas, the proportion of untreated diabetic patients with decreased PT, aPTT and platelet count was 20%, 85 and 7.5% of respectively (Fig. 1a, b & c) ).
The mean aPTT of non-diabetic, treated and untreated type II diabetic patient was 32.8 ± 4.12 s, 34.4 ± 5.3 s, and 25.42 ± 8.46 s, respectively. Similarly, the mean PT of non-diabetic controls, treated type II DM and untreated DM were 14.28 ± 1.50 s, 14.65 ± 2.50 s and 13.54 ± 3.44 s, respectively. Moreover, the platelet count of non-diabetic control, treated type II DM, and untreated DM were 251,000 ± 71,964, 254,000 ± 95,077 and 250,000 ± 75,546, respectively. The study subjects had significantly different aPTT among the three groups in the ANOVA test (F: 60.7; P < 0.001).There was a significant shortening of aPTT in untreated diabetic as compared to both treated and non-diabetic controls (P < 0.001). However, the mean aPTT, PT and platelet count were not significant between treated type II DM patients and nondiabetic individuals (P > 0.05) ( Table 2 ).
Discussion
In this study, non-diabetic, treated and untreated diabetic have a mean aPTT of 32.79 ± 4.12 s, 34.45 ± 5.35 s, and 25.42 ± 8.46 s, respectively. There was a significant shortening of aPTT in untreated diabetic patients compared to either treated or non-diabetic individuals (P < 0.001). Similar findings were reported by Zhao et al... among patients in China [10] , by Chavan et al. in India [11] , Acang et al. in Indonesia [12] and Ankalayya et al in India [13] that described shortening of aPTT in type II DM patients is a high risk of hypercoagulable state. This may happen due to the glycation of intrinsic clotting factors caused by the presence of persistent hyperglycemia in untreated DM patients. Persistent hyperglycemia may result the glycation of intracellular and extracellular protein that will change the normal functioning of these proteins which affect their clotting capacity [14] . Thus, glycation of clotting factors may result the activation of inactive intrinsic factors which finally results the shortening of aPTT [15] . However, PT of untreated DM patients was not found significantly associated in this study when compared to treated type II DM patients (P = 0.274) and non-diabetic individuals (P = 0.759). The insignificant PT results support the hypothesis that there is less involvement of the extrinsic pathway in hypercoagulability state in diabetic conditions due to the fact that injury occurring to the vascular system in diabetic patients does not involve the release of tissue factor from outside of the vascular system [16] . APTT but not PT would be affected by the glycation method. Hypercoagulability detected by shortened APTT values was independently associated with venous thromboembolism (VTE) and hypothesized that shortened APTT could be considered as a risk marker for VTE [17] . This entails that APTT is a better predictor of hypercoagulable state than PT in T2DM patients [18] which have any impact on the management of these patients.
The current study also showed that there was no significant difference of the mean PT, aPTT and platelet count between treated and non-diabetic individuals (P > 0.05). This might be due to the effect of non-insulin hypoglycemic drug on glucose level which in turn prevents glycation process in treated DM patients.
In this study, the mean PT and platelet count of treated; untreated diabetic patients and non-diabetic individuals had shown no significant difference among the groups (P > 0.05). Similarly, studies conducted in Iran by Soltani et al. [16] and in Nigeria by Ifeanyi et al. [19] reported no significant difference of PT findings among the groups, and Ephraim et al. [20] also reported mean platelet count was within the normal range among study subjects in Ghana.
Moreover, 12.5% of untreated diabetic had a decreased PT compared to no decreased PT in treated diabetic patients. About 85% of untreated diabetic had a decreased aPTT whereas only 2.5% of treated diabetic had a decreased aPTT. This finding indicates that those treated type II diabetic patients had properly control their blood glucose level than untreated individuals. This may be due to association of glycation, a nonenzymatic binding of glucose on protein, with the persistence hyper glycemia that could change the normal function of the intrinsic factors (aPTT) and the extrinsic factors (PT) [14] .
Conclusions
There was a significant shortening of aPTT in untreated diabetic patients as compared with treated and non-diabetic groups. Therefore, shortening of aPTT in untreated type II diabetic patients might be useful marker in patients with diabetes. Monitoring of the aPTT in newly diagnosed diabetic patients is important to prevent hypercoagulation.
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